Top 10 Abstracts from ASCO 2020 with Milind Javle

Milind M. Javle

Top 10 Abstracts from ASCO 2020 with Milind Javle

ASCO Highlights

Videos — June 3, 2020

Featuring:

Milind M. Javle, MD

Hubert L. and Olive Stringer Professor
GI Medical Oncology
University of Texas MD Anderson
Cancer Center, Houston
Chair, NCI Task Force,
Hepatobiliary Cancers

Treatment options for cholangiocarcinoma continue to evolve. Milind Javle, MD, from MD Anderson Cancer Center, discusses some interesting abstracts from the ASCO 2020 meeting.

By Milind M. Javle, MD

Letter from the Editor-in-Chief

December 2025, Vol 6, No 4

Welcome to the final edition of CCA News for this season. This end-of-season issue reflects highlights from the 2025 Cholangiocarcinoma (CCA) Summit held in Scottsdale, AZ, where international experts presented leading advances in CCA.

Advancing Cholangiocarcinoma Care: Breakthroughs in Targeted Therapies, Immunotherapy, and Early Detection

By Milind M. Javle, MD

Letter from the Editor-in-Chief

September 2025, Vol 6, No 3

Groundbreaking advancements in cholangiocarcinoma research, including targeted therapies, immunotherapy innovations, and promising early detection strategies, are highlighted in this issue.

ADJUBIL: A Phase 2 Trial of Durvalumab and Tremelimumab With or Without Capecitabine as Adjuvant Therapy for BTC

ASCO Highlights

September 2025, Vol 6, No 3

The ADJUBIL trial reveals that dual immune checkpoint blockade with durvalumab and tremelimumab without capecitabine offers a promising adjuvant therapy option with minimal toxicity for resectable biliary tract cancer.

TP53 Mutations in BTC: A Prognostic Marker and a Potential Target for Immune Checkpoint Inhibitors

ASCO Highlights

September 2025, Vol 6, No 3

Patients with TP53-mutated biliary tract cancer may have poorer prognoses but show enhanced responsiveness to immune checkpoint inhibitors, offering hope for tailored therapeutic strategies.

Triplet Immunotherapy in Advanced Hepatocellular and Biliary Tract Cancers

ASCO Highlights

September 2025, Vol 6, No 3

A novel triplet immunotherapy combining durvalumab, bevacizumab, and tremelimumab shows potential for improving survival in advanced hepatocellular and biliary tract cancers.

Rilvegostomig Plus Chemotherapy in Advanced Biliary Tract Cancer

ASCO Highlights

September 2025, Vol 6, No 3

A novel bispecific antibody, rilvegostomig, combined with chemotherapy shows promising efficacy and safety in improving outcomes for patients with advanced biliary tract cancer.

Zanidatamab-hrii Extends Survival in Previously Treated HER2-Positive BTC

ASCO Highlights

September 2025, Vol 6, No 3

Zanidatamab-hrii significantly improves survival in HER2-positive biliary tract cancer, offering new hope for patients with limited second-line treatment options.

Real-World Outcomes of Ivosidenib in IDH1-Mutated CCA: A Study in US Veterans

ASCO Highlights

September 2025, Vol 6, No 3

Real-world data from US veterans confirm the safety and efficacy of ivosidenib in treating IDH1-mutated cholangiocarcinoma, offering hope for improved outcomes in this challenging cancer.

Initial Findings From a Phase 2 Trial on Trifluridine/Tipiracil Combined With Irinotecan as Second-Line Therapy for CCA

ASCO Highlights

September 2025, Vol 6, No 3

The TRITICC trial highlights a promising second-line therapy with trifluridine, tipiracil, and irinotecan for advanced cholangiocarcinoma, offering hope after failure of first-line treatment.

Advancing Early Detection of BTC Using cfDNA Fragmentomics and Machine Learning

ASCO Highlights

September 2025, Vol 6, No 3

A cutting-edge circulating cell-free DNA fragmentomics approach combined with machine learning offers a noninvasive method for early detection of biliary tract cancer.

Top 10 Abstracts from ASCO 2020 with Milind Javle

Featuring:

Subscribe Today!

I'd like to receive:

Stay In The Know

Top 10 Abstracts from ASCO 2020 with Milind Javle

Featuring:

Related Items

Subscribe Today!

I'd like to receive:

Stay In The Know

We Value Your Feedback! Tell Us How You Consume Content